nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—SLCO1B3—Methotrexate—bone cancer	0.192	0.231	CbGbCtD
Olmesartan—ABCC2—Carboplatin—bone cancer	0.177	0.213	CbGbCtD
Olmesartan—ABCC2—Cisplatin—bone cancer	0.151	0.182	CbGbCtD
Olmesartan—SLCO1B1—Methotrexate—bone cancer	0.112	0.134	CbGbCtD
Olmesartan—ABCC2—Doxorubicin—bone cancer	0.101	0.122	CbGbCtD
Olmesartan—ABCC2—Methotrexate—bone cancer	0.0981	0.118	CbGbCtD
Olmesartan—Irbesartan—JUN—bone cancer	0.00574	0.652	CrCbGaD
Olmesartan—ABCC2—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00147	0.0878	CbGpPWpGaD
Olmesartan—Tasosartan—CYP3A4—bone cancer	0.00147	0.167	CrCbGaD
Olmesartan—SLCO1B1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00138	0.0825	CbGpPWpGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00138	0.0823	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00129	0.0773	CbGpPWpGaD
Olmesartan—Irbesartan—CYP3A4—bone cancer	0.000966	0.11	CrCbGaD
Olmesartan—ABCC2—Irinotecan Pathway—CYP3A4—bone cancer	0.00094	0.0561	CbGpPWpGaD
Olmesartan—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.000883	0.0527	CbGpPWpGaD
Olmesartan—ABCC2—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000805	0.0481	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 signaling events—GNA11—bone cancer	0.000798	0.0477	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000791	0.0472	CbGpPWpGaD
Olmesartan—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000756	0.0451	CbGpPWpGaD
Olmesartan—Losartan—CYP3A4—bone cancer	0.000623	0.0708	CrCbGaD
Olmesartan—ABCC2—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000485	0.029	CbGpPWpGaD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000462	0.0276	CbGpPWpGaD
Olmesartan—AGTR1—Arf6 signaling events—MET—bone cancer	0.000449	0.0268	CbGpPWpGaD
Olmesartan—Hypotension—Cisplatin—bone cancer	0.000414	0.00288	CcSEcCtD
Olmesartan—Nasopharyngitis—Epirubicin—bone cancer	0.000414	0.00288	CcSEcCtD
Olmesartan—Face oedema—Doxorubicin—bone cancer	0.000413	0.00288	CcSEcCtD
Olmesartan—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000408	0.00284	CcSEcCtD
Olmesartan—Pancytopenia—Methotrexate—bone cancer	0.000406	0.00283	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000404	0.00281	CcSEcCtD
Olmesartan—Blood creatinine increased—Doxorubicin—bone cancer	0.000401	0.00279	CcSEcCtD
Olmesartan—Influenza—Epirubicin—bone cancer	0.0004	0.00279	CcSEcCtD
Olmesartan—Neutropenia—Methotrexate—bone cancer	0.0004	0.00278	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Methotrexate—bone cancer	0.000397	0.00277	CcSEcCtD
Olmesartan—Eosinophilia—Epirubicin—bone cancer	0.000396	0.00276	CcSEcCtD
Olmesartan—Erectile dysfunction—Methotrexate—bone cancer	0.000394	0.00274	CcSEcCtD
Olmesartan—Pancreatitis—Epirubicin—bone cancer	0.000392	0.00273	CcSEcCtD
Olmesartan—Orthostatic hypotension—Doxorubicin—bone cancer	0.000391	0.00272	CcSEcCtD
Olmesartan—Photosensitivity reaction—Methotrexate—bone cancer	0.00039	0.00272	CcSEcCtD
Olmesartan—Hypokalaemia—Doxorubicin—bone cancer	0.00039	0.00271	CcSEcCtD
Olmesartan—Angina pectoris—Epirubicin—bone cancer	0.00039	0.00271	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Doxorubicin—bone cancer	0.000386	0.00269	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000386	0.00269	CcSEcCtD
Olmesartan—Decreased appetite—Cisplatin—bone cancer	0.000385	0.00268	CcSEcCtD
Olmesartan—Bronchitis—Epirubicin—bone cancer	0.000385	0.00268	CcSEcCtD
Olmesartan—Pneumonia—Methotrexate—bone cancer	0.000383	0.00267	CcSEcCtD
Olmesartan—Nasopharyngitis—Doxorubicin—bone cancer	0.000383	0.00267	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Cisplatin—bone cancer	0.000382	0.00266	CcSEcCtD
Olmesartan—Infestation—Methotrexate—bone cancer	0.000381	0.00265	CcSEcCtD
Olmesartan—Infestation NOS—Methotrexate—bone cancer	0.000381	0.00265	CcSEcCtD
Olmesartan—Pancytopenia—Epirubicin—bone cancer	0.00038	0.00265	CcSEcCtD
Olmesartan—Pain—Cisplatin—bone cancer	0.000379	0.00264	CcSEcCtD
Olmesartan—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000378	0.00263	CcSEcCtD
Olmesartan—Renal failure—Methotrexate—bone cancer	0.000375	0.00261	CcSEcCtD
Olmesartan—Neutropenia—Epirubicin—bone cancer	0.000374	0.00261	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Epirubicin—bone cancer	0.000372	0.00259	CcSEcCtD
Olmesartan—Influenza—Doxorubicin—bone cancer	0.00037	0.00258	CcSEcCtD
Olmesartan—Eosinophilia—Doxorubicin—bone cancer	0.000366	0.00255	CcSEcCtD
Olmesartan—Photosensitivity reaction—Epirubicin—bone cancer	0.000365	0.00254	CcSEcCtD
Olmesartan—Feeling abnormal—Cisplatin—bone cancer	0.000365	0.00254	CcSEcCtD
Olmesartan—Haematuria—Methotrexate—bone cancer	0.000363	0.00253	CcSEcCtD
Olmesartan—Pancreatitis—Doxorubicin—bone cancer	0.000363	0.00253	CcSEcCtD
Olmesartan—Hyperglycaemia—Epirubicin—bone cancer	0.000361	0.00251	CcSEcCtD
Olmesartan—Angina pectoris—Doxorubicin—bone cancer	0.000361	0.00251	CcSEcCtD
Olmesartan—Pneumonia—Epirubicin—bone cancer	0.000359	0.0025	CcSEcCtD
Olmesartan—Infestation—Epirubicin—bone cancer	0.000357	0.00248	CcSEcCtD
Olmesartan—Infestation NOS—Epirubicin—bone cancer	0.000357	0.00248	CcSEcCtD
Olmesartan—Bronchitis—Doxorubicin—bone cancer	0.000356	0.00248	CcSEcCtD
Olmesartan—Agranulocytosis—Methotrexate—bone cancer	0.000356	0.00248	CcSEcCtD
Olmesartan—Pancytopenia—Doxorubicin—bone cancer	0.000352	0.00245	CcSEcCtD
Olmesartan—Renal failure—Epirubicin—bone cancer	0.000351	0.00244	CcSEcCtD
Olmesartan—Body temperature increased—Cisplatin—bone cancer	0.00035	0.00244	CcSEcCtD
Olmesartan—Jaundice—Epirubicin—bone cancer	0.000348	0.00242	CcSEcCtD
Olmesartan—Urinary tract infection—Epirubicin—bone cancer	0.000347	0.00242	CcSEcCtD
Olmesartan—Neutropenia—Doxorubicin—bone cancer	0.000346	0.00241	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000344	0.0024	CcSEcCtD
Olmesartan—Haematuria—Epirubicin—bone cancer	0.00034	0.00237	CcSEcCtD
Olmesartan—Pharyngitis—Methotrexate—bone cancer	0.00034	0.00237	CcSEcCtD
Olmesartan—Urinary tract disorder—Methotrexate—bone cancer	0.000338	0.00235	CcSEcCtD
Olmesartan—Photosensitivity reaction—Doxorubicin—bone cancer	0.000338	0.00235	CcSEcCtD
Olmesartan—Urethral disorder—Methotrexate—bone cancer	0.000335	0.00234	CcSEcCtD
Olmesartan—Sinusitis—Epirubicin—bone cancer	0.000335	0.00233	CcSEcCtD
Olmesartan—Hyperglycaemia—Doxorubicin—bone cancer	0.000334	0.00233	CcSEcCtD
Olmesartan—Agranulocytosis—Epirubicin—bone cancer	0.000333	0.00232	CcSEcCtD
Olmesartan—Pneumonia—Doxorubicin—bone cancer	0.000332	0.00231	CcSEcCtD
Olmesartan—Infestation—Doxorubicin—bone cancer	0.00033	0.0023	CcSEcCtD
Olmesartan—Infestation NOS—Doxorubicin—bone cancer	0.00033	0.0023	CcSEcCtD
Olmesartan—Renal failure—Doxorubicin—bone cancer	0.000324	0.00226	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—GRM1—bone cancer	0.000324	0.0194	CbGpPWpGaD
Olmesartan—Jaundice—Doxorubicin—bone cancer	0.000322	0.00224	CcSEcCtD
Olmesartan—Rhinitis—Epirubicin—bone cancer	0.000321	0.00224	CcSEcCtD
Olmesartan—Urinary tract infection—Doxorubicin—bone cancer	0.000321	0.00223	CcSEcCtD
Olmesartan—Asthenia—Cisplatin—bone cancer	0.000318	0.00221	CcSEcCtD
Olmesartan—Pharyngitis—Epirubicin—bone cancer	0.000318	0.00221	CcSEcCtD
Olmesartan—Urinary tract disorder—Epirubicin—bone cancer	0.000316	0.0022	CcSEcCtD
Olmesartan—Oedema peripheral—Epirubicin—bone cancer	0.000315	0.0022	CcSEcCtD
Olmesartan—Haematuria—Doxorubicin—bone cancer	0.000315	0.00219	CcSEcCtD
Olmesartan—Connective tissue disorder—Epirubicin—bone cancer	0.000315	0.00219	CcSEcCtD
Olmesartan—Urethral disorder—Epirubicin—bone cancer	0.000314	0.00219	CcSEcCtD
Olmesartan—Angiopathy—Methotrexate—bone cancer	0.00031	0.00216	CcSEcCtD
Olmesartan—Sinusitis—Doxorubicin—bone cancer	0.00031	0.00216	CcSEcCtD
Olmesartan—Mediastinal disorder—Methotrexate—bone cancer	0.000308	0.00215	CcSEcCtD
Olmesartan—Agranulocytosis—Doxorubicin—bone cancer	0.000308	0.00215	CcSEcCtD
Olmesartan—Diarrhoea—Cisplatin—bone cancer	0.000303	0.00211	CcSEcCtD
Olmesartan—Alopecia—Methotrexate—bone cancer	0.000302	0.00211	CcSEcCtD
Olmesartan—Mental disorder—Methotrexate—bone cancer	0.0003	0.00209	CcSEcCtD
Olmesartan—Malnutrition—Methotrexate—bone cancer	0.000298	0.00207	CcSEcCtD
Olmesartan—Rhinitis—Doxorubicin—bone cancer	0.000297	0.00207	CcSEcCtD
Olmesartan—Pharyngitis—Doxorubicin—bone cancer	0.000294	0.00205	CcSEcCtD
Olmesartan—Urinary tract disorder—Doxorubicin—bone cancer	0.000293	0.00204	CcSEcCtD
Olmesartan—Oedema peripheral—Doxorubicin—bone cancer	0.000292	0.00203	CcSEcCtD
Olmesartan—Connective tissue disorder—Doxorubicin—bone cancer	0.000291	0.00203	CcSEcCtD
Olmesartan—Angiopathy—Epirubicin—bone cancer	0.000291	0.00202	CcSEcCtD
Olmesartan—Urethral disorder—Doxorubicin—bone cancer	0.00029	0.00202	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00029	0.0173	CbGpPWpGaD
Olmesartan—Mediastinal disorder—Epirubicin—bone cancer	0.000289	0.00201	CcSEcCtD
Olmesartan—Back pain—Methotrexate—bone cancer	0.000288	0.00201	CcSEcCtD
Olmesartan—Arrhythmia—Epirubicin—bone cancer	0.000286	0.00199	CcSEcCtD
Olmesartan—Alopecia—Epirubicin—bone cancer	0.000283	0.00197	CcSEcCtD
Olmesartan—Vomiting—Cisplatin—bone cancer	0.000282	0.00196	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—bone cancer	0.000281	0.0168	CbGpPWpGaD
Olmesartan—Vision blurred—Methotrexate—bone cancer	0.000281	0.00196	CcSEcCtD
Olmesartan—Mental disorder—Epirubicin—bone cancer	0.000281	0.00195	CcSEcCtD
Olmesartan—Rash—Cisplatin—bone cancer	0.000279	0.00195	CcSEcCtD
Olmesartan—Dermatitis—Cisplatin—bone cancer	0.000279	0.00194	CcSEcCtD
Olmesartan—Malnutrition—Epirubicin—bone cancer	0.000279	0.00194	CcSEcCtD
Olmesartan—Ill-defined disorder—Methotrexate—bone cancer	0.000276	0.00193	CcSEcCtD
Olmesartan—Anaemia—Methotrexate—bone cancer	0.000275	0.00192	CcSEcCtD
Olmesartan—Back pain—Epirubicin—bone cancer	0.00027	0.00188	CcSEcCtD
Olmesartan—Angiopathy—Doxorubicin—bone cancer	0.000269	0.00187	CcSEcCtD
Olmesartan—Malaise—Methotrexate—bone cancer	0.000269	0.00187	CcSEcCtD
Olmesartan—Muscle spasms—Epirubicin—bone cancer	0.000268	0.00187	CcSEcCtD
Olmesartan—Vertigo—Methotrexate—bone cancer	0.000268	0.00186	CcSEcCtD
Olmesartan—Mediastinal disorder—Doxorubicin—bone cancer	0.000267	0.00186	CcSEcCtD
Olmesartan—Leukopenia—Methotrexate—bone cancer	0.000267	0.00186	CcSEcCtD
Olmesartan—Arrhythmia—Doxorubicin—bone cancer	0.000265	0.00184	CcSEcCtD
Olmesartan—Nausea—Cisplatin—bone cancer	0.000263	0.00183	CcSEcCtD
Olmesartan—Vision blurred—Epirubicin—bone cancer	0.000263	0.00183	CcSEcCtD
Olmesartan—Alopecia—Doxorubicin—bone cancer	0.000262	0.00182	CcSEcCtD
Olmesartan—Cough—Methotrexate—bone cancer	0.00026	0.00181	CcSEcCtD
Olmesartan—Mental disorder—Doxorubicin—bone cancer	0.00026	0.00181	CcSEcCtD
Olmesartan—Ill-defined disorder—Epirubicin—bone cancer	0.000259	0.0018	CcSEcCtD
Olmesartan—Malnutrition—Doxorubicin—bone cancer	0.000258	0.0018	CcSEcCtD
Olmesartan—Anaemia—Epirubicin—bone cancer	0.000258	0.00179	CcSEcCtD
Olmesartan—Agitation—Epirubicin—bone cancer	0.000256	0.00178	CcSEcCtD
Olmesartan—Arthralgia—Methotrexate—bone cancer	0.000254	0.00177	CcSEcCtD
Olmesartan—Myalgia—Methotrexate—bone cancer	0.000254	0.00177	CcSEcCtD
Olmesartan—Chest pain—Methotrexate—bone cancer	0.000254	0.00177	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000252	0.00175	CcSEcCtD
Olmesartan—Malaise—Epirubicin—bone cancer	0.000251	0.00175	CcSEcCtD
Olmesartan—Discomfort—Methotrexate—bone cancer	0.000251	0.00175	CcSEcCtD
Olmesartan—Vertigo—Epirubicin—bone cancer	0.00025	0.00174	CcSEcCtD
Olmesartan—Syncope—Epirubicin—bone cancer	0.00025	0.00174	CcSEcCtD
Olmesartan—Leukopenia—Epirubicin—bone cancer	0.00025	0.00174	CcSEcCtD
Olmesartan—Back pain—Doxorubicin—bone cancer	0.000249	0.00174	CcSEcCtD
Olmesartan—Muscle spasms—Doxorubicin—bone cancer	0.000248	0.00173	CcSEcCtD
Olmesartan—Palpitations—Epirubicin—bone cancer	0.000246	0.00172	CcSEcCtD
Olmesartan—Loss of consciousness—Epirubicin—bone cancer	0.000245	0.00171	CcSEcCtD
Olmesartan—Cough—Epirubicin—bone cancer	0.000243	0.00169	CcSEcCtD
Olmesartan—Anaphylactic shock—Methotrexate—bone cancer	0.000243	0.00169	CcSEcCtD
Olmesartan—Vision blurred—Doxorubicin—bone cancer	0.000243	0.00169	CcSEcCtD
Olmesartan—Infection—Methotrexate—bone cancer	0.000242	0.00168	CcSEcCtD
Olmesartan—Ill-defined disorder—Doxorubicin—bone cancer	0.000239	0.00167	CcSEcCtD
Olmesartan—Nervous system disorder—Methotrexate—bone cancer	0.000238	0.00166	CcSEcCtD
Olmesartan—Anaemia—Doxorubicin—bone cancer	0.000238	0.00166	CcSEcCtD
Olmesartan—Thrombocytopenia—Methotrexate—bone cancer	0.000238	0.00166	CcSEcCtD
Olmesartan—Chest pain—Epirubicin—bone cancer	0.000237	0.00165	CcSEcCtD
Olmesartan—Myalgia—Epirubicin—bone cancer	0.000237	0.00165	CcSEcCtD
Olmesartan—Arthralgia—Epirubicin—bone cancer	0.000237	0.00165	CcSEcCtD
Olmesartan—Agitation—Doxorubicin—bone cancer	0.000237	0.00165	CcSEcCtD
Olmesartan—Anxiety—Epirubicin—bone cancer	0.000236	0.00165	CcSEcCtD
Olmesartan—Skin disorder—Methotrexate—bone cancer	0.000236	0.00164	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000236	0.00164	CcSEcCtD
Olmesartan—Hyperhidrosis—Methotrexate—bone cancer	0.000235	0.00164	CcSEcCtD
Olmesartan—Discomfort—Epirubicin—bone cancer	0.000234	0.00163	CcSEcCtD
Olmesartan—Malaise—Doxorubicin—bone cancer	0.000233	0.00162	CcSEcCtD
Olmesartan—Vertigo—Doxorubicin—bone cancer	0.000232	0.00161	CcSEcCtD
Olmesartan—Anorexia—Methotrexate—bone cancer	0.000232	0.00161	CcSEcCtD
Olmesartan—Syncope—Doxorubicin—bone cancer	0.000231	0.00161	CcSEcCtD
Olmesartan—Leukopenia—Doxorubicin—bone cancer	0.000231	0.00161	CcSEcCtD
Olmesartan—Palpitations—Doxorubicin—bone cancer	0.000228	0.00159	CcSEcCtD
Olmesartan—Anaphylactic shock—Epirubicin—bone cancer	0.000227	0.00158	CcSEcCtD
Olmesartan—Oedema—Epirubicin—bone cancer	0.000227	0.00158	CcSEcCtD
Olmesartan—AGTR1—Arf6 signaling events—EGFR—bone cancer	0.000227	0.0136	CbGpPWpGaD
Olmesartan—Hypotension—Methotrexate—bone cancer	0.000227	0.00158	CcSEcCtD
Olmesartan—Loss of consciousness—Doxorubicin—bone cancer	0.000227	0.00158	CcSEcCtD
Olmesartan—Infection—Epirubicin—bone cancer	0.000226	0.00157	CcSEcCtD
Olmesartan—Cough—Doxorubicin—bone cancer	0.000225	0.00157	CcSEcCtD
Olmesartan—Shock—Epirubicin—bone cancer	0.000224	0.00156	CcSEcCtD
Olmesartan—Nervous system disorder—Epirubicin—bone cancer	0.000223	0.00155	CcSEcCtD
Olmesartan—Thrombocytopenia—Epirubicin—bone cancer	0.000223	0.00155	CcSEcCtD
Olmesartan—Tachycardia—Epirubicin—bone cancer	0.000222	0.00155	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000221	0.00154	CcSEcCtD
Olmesartan—Skin disorder—Epirubicin—bone cancer	0.000221	0.00154	CcSEcCtD
Olmesartan—Hyperhidrosis—Epirubicin—bone cancer	0.00022	0.00153	CcSEcCtD
Olmesartan—Insomnia—Methotrexate—bone cancer	0.00022	0.00153	CcSEcCtD
Olmesartan—Arthralgia—Doxorubicin—bone cancer	0.00022	0.00153	CcSEcCtD
Olmesartan—Chest pain—Doxorubicin—bone cancer	0.00022	0.00153	CcSEcCtD
Olmesartan—Myalgia—Doxorubicin—bone cancer	0.00022	0.00153	CcSEcCtD
Olmesartan—Anxiety—Doxorubicin—bone cancer	0.000219	0.00152	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000218	0.00152	CcSEcCtD
Olmesartan—Discomfort—Doxorubicin—bone cancer	0.000217	0.00151	CcSEcCtD
Olmesartan—Anorexia—Epirubicin—bone cancer	0.000217	0.00151	CcSEcCtD
Olmesartan—Dyspepsia—Methotrexate—bone cancer	0.000214	0.00149	CcSEcCtD
Olmesartan—Hypotension—Epirubicin—bone cancer	0.000213	0.00148	CcSEcCtD
Olmesartan—Decreased appetite—Methotrexate—bone cancer	0.000211	0.00147	CcSEcCtD
Olmesartan—Anaphylactic shock—Doxorubicin—bone cancer	0.00021	0.00147	CcSEcCtD
Olmesartan—Oedema—Doxorubicin—bone cancer	0.00021	0.00147	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Methotrexate—bone cancer	0.00021	0.00146	CcSEcCtD
Olmesartan—Fatigue—Methotrexate—bone cancer	0.00021	0.00146	CcSEcCtD
Olmesartan—Infection—Doxorubicin—bone cancer	0.000209	0.00146	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—GNA11—bone cancer	0.000209	0.0125	CbGpPWpGaD
Olmesartan—Pain—Methotrexate—bone cancer	0.000208	0.00145	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000207	0.00144	CcSEcCtD
Olmesartan—Shock—Doxorubicin—bone cancer	0.000207	0.00144	CcSEcCtD
Olmesartan—Nervous system disorder—Doxorubicin—bone cancer	0.000206	0.00144	CcSEcCtD
Olmesartan—Thrombocytopenia—Doxorubicin—bone cancer	0.000206	0.00144	CcSEcCtD
Olmesartan—Insomnia—Epirubicin—bone cancer	0.000206	0.00143	CcSEcCtD
Olmesartan—Tachycardia—Doxorubicin—bone cancer	0.000205	0.00143	CcSEcCtD
Olmesartan—Skin disorder—Doxorubicin—bone cancer	0.000204	0.00142	CcSEcCtD
Olmesartan—Hyperhidrosis—Doxorubicin—bone cancer	0.000203	0.00142	CcSEcCtD
Olmesartan—Anorexia—Doxorubicin—bone cancer	0.000201	0.0014	CcSEcCtD
Olmesartan—Feeling abnormal—Methotrexate—bone cancer	0.0002	0.0014	CcSEcCtD
Olmesartan—Dyspepsia—Epirubicin—bone cancer	0.0002	0.00139	CcSEcCtD
Olmesartan—Gastrointestinal pain—Methotrexate—bone cancer	0.000199	0.00138	CcSEcCtD
Olmesartan—Decreased appetite—Epirubicin—bone cancer	0.000198	0.00138	CcSEcCtD
Olmesartan—Hypotension—Doxorubicin—bone cancer	0.000197	0.00137	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Epirubicin—bone cancer	0.000196	0.00137	CcSEcCtD
Olmesartan—Fatigue—Epirubicin—bone cancer	0.000196	0.00137	CcSEcCtD
Olmesartan—Pain—Epirubicin—bone cancer	0.000195	0.00136	CcSEcCtD
Olmesartan—Constipation—Epirubicin—bone cancer	0.000195	0.00136	CcSEcCtD
Olmesartan—Urticaria—Methotrexate—bone cancer	0.000193	0.00135	CcSEcCtD
Olmesartan—Abdominal pain—Methotrexate—bone cancer	0.000192	0.00134	CcSEcCtD
Olmesartan—Body temperature increased—Methotrexate—bone cancer	0.000192	0.00134	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000192	0.00134	CcSEcCtD
Olmesartan—Insomnia—Doxorubicin—bone cancer	0.00019	0.00133	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—GRM4—bone cancer	0.000189	0.0113	CbGpPWpGaD
Olmesartan—Feeling abnormal—Epirubicin—bone cancer	0.000187	0.00131	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000187	0.0112	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Epirubicin—bone cancer	0.000186	0.0013	CcSEcCtD
Olmesartan—Dyspepsia—Doxorubicin—bone cancer	0.000185	0.00129	CcSEcCtD
Olmesartan—Decreased appetite—Doxorubicin—bone cancer	0.000183	0.00127	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000182	0.00127	CcSEcCtD
Olmesartan—Fatigue—Doxorubicin—bone cancer	0.000181	0.00126	CcSEcCtD
Olmesartan—Urticaria—Epirubicin—bone cancer	0.000181	0.00126	CcSEcCtD
Olmesartan—Pain—Doxorubicin—bone cancer	0.00018	0.00125	CcSEcCtD
Olmesartan—Constipation—Doxorubicin—bone cancer	0.00018	0.00125	CcSEcCtD
Olmesartan—Body temperature increased—Epirubicin—bone cancer	0.00018	0.00125	CcSEcCtD
Olmesartan—Abdominal pain—Epirubicin—bone cancer	0.00018	0.00125	CcSEcCtD
Olmesartan—Asthenia—Methotrexate—bone cancer	0.000174	0.00121	CcSEcCtD
Olmesartan—Feeling abnormal—Doxorubicin—bone cancer	0.000173	0.00121	CcSEcCtD
Olmesartan—Gastrointestinal pain—Doxorubicin—bone cancer	0.000172	0.0012	CcSEcCtD
Olmesartan—Pruritus—Methotrexate—bone cancer	0.000172	0.0012	CcSEcCtD
Olmesartan—Urticaria—Doxorubicin—bone cancer	0.000167	0.00116	CcSEcCtD
Olmesartan—Abdominal pain—Doxorubicin—bone cancer	0.000166	0.00116	CcSEcCtD
Olmesartan—Body temperature increased—Doxorubicin—bone cancer	0.000166	0.00116	CcSEcCtD
Olmesartan—Diarrhoea—Methotrexate—bone cancer	0.000166	0.00116	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—GRM1—bone cancer	0.000164	0.00976	CbGpPWpGaD
Olmesartan—Asthenia—Epirubicin—bone cancer	0.000163	0.00114	CcSEcCtD
Olmesartan—Pruritus—Epirubicin—bone cancer	0.000161	0.00112	CcSEcCtD
Olmesartan—Dizziness—Methotrexate—bone cancer	0.000161	0.00112	CcSEcCtD
Olmesartan—Diarrhoea—Epirubicin—bone cancer	0.000156	0.00108	CcSEcCtD
Olmesartan—Vomiting—Methotrexate—bone cancer	0.000155	0.00108	CcSEcCtD
Olmesartan—Rash—Methotrexate—bone cancer	0.000153	0.00107	CcSEcCtD
Olmesartan—Dermatitis—Methotrexate—bone cancer	0.000153	0.00107	CcSEcCtD
Olmesartan—Headache—Methotrexate—bone cancer	0.000152	0.00106	CcSEcCtD
Olmesartan—Asthenia—Doxorubicin—bone cancer	0.000151	0.00105	CcSEcCtD
Olmesartan—Dizziness—Epirubicin—bone cancer	0.00015	0.00105	CcSEcCtD
Olmesartan—Pruritus—Doxorubicin—bone cancer	0.000149	0.00104	CcSEcCtD
Olmesartan—Vomiting—Epirubicin—bone cancer	0.000145	0.00101	CcSEcCtD
Olmesartan—Nausea—Methotrexate—bone cancer	0.000144	0.00101	CcSEcCtD
Olmesartan—Diarrhoea—Doxorubicin—bone cancer	0.000144	0.001	CcSEcCtD
Olmesartan—Rash—Epirubicin—bone cancer	0.000143	0.000999	CcSEcCtD
Olmesartan—Dermatitis—Epirubicin—bone cancer	0.000143	0.000998	CcSEcCtD
Olmesartan—Headache—Epirubicin—bone cancer	0.000143	0.000993	CcSEcCtD
Olmesartan—Dizziness—Doxorubicin—bone cancer	0.000139	0.00097	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000135	0.00809	CbGpPWpGaD
Olmesartan—Nausea—Epirubicin—bone cancer	0.000135	0.000941	CcSEcCtD
Olmesartan—Vomiting—Doxorubicin—bone cancer	0.000134	0.000932	CcSEcCtD
Olmesartan—Rash—Doxorubicin—bone cancer	0.000133	0.000924	CcSEcCtD
Olmesartan—Dermatitis—Doxorubicin—bone cancer	0.000133	0.000924	CcSEcCtD
Olmesartan—Headache—Doxorubicin—bone cancer	0.000132	0.000919	CcSEcCtD
Olmesartan—Nausea—Doxorubicin—bone cancer	0.000125	0.000871	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000123	0.00736	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000123	0.00736	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000117	0.00698	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—SMO—bone cancer	0.000115	0.00688	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—RGS1—bone cancer	0.000107	0.00636	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GRM4—bone cancer	0.000107	0.00636	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NDUFA12—bone cancer	0.000106	0.00632	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.69e-05	0.00578	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GRM4—bone cancer	9.68e-05	0.00578	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—RGS1—bone cancer	9.68e-05	0.00578	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GRM1—bone cancer	9.24e-05	0.00552	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.1e-05	0.00543	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NT5C3A—bone cancer	8.78e-05	0.00524	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GRM1—bone cancer	8.39e-05	0.00501	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.37e-05	0.00499	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.86e-05	0.00469	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NDUFA12—bone cancer	7.12e-05	0.00425	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—GNA11—bone cancer	5.95e-05	0.00355	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—SMO—bone cancer	5.91e-05	0.00353	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NT5C3A—bone cancer	5.9e-05	0.00352	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GRM4—bone cancer	5.72e-05	0.00341	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RGS1—bone cancer	5.72e-05	0.00341	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—GNA11—bone cancer	5.41e-05	0.00323	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—IL3—bone cancer	5.4e-05	0.00322	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	5.32e-05	0.00318	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GRM1—bone cancer	4.96e-05	0.00296	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL3—bone cancer	4.9e-05	0.00293	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ENO2—bone cancer	3.84e-05	0.00229	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—DHFR—bone cancer	3.57e-05	0.00213	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SMO—bone cancer	3.49e-05	0.00208	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GNA11—bone cancer	3.33e-05	0.00199	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—GNA11—bone cancer	3.19e-05	0.00191	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP3A4—bone cancer	3.02e-05	0.0018	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.01e-05	0.00179	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ATF1—bone cancer	2.97e-05	0.00177	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL3—bone cancer	2.9e-05	0.00173	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTP1—bone cancer	2.58e-05	0.00154	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ENO2—bone cancer	2.58e-05	0.00154	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFBR2—bone cancer	2.48e-05	0.00148	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—DHFR—bone cancer	2.4e-05	0.00143	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IGF1R—bone cancer	2.33e-05	0.00139	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GNA11—bone cancer	2.24e-05	0.00134	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP3A4—bone cancer	2.03e-05	0.00121	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.02e-05	0.00121	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTP1—bone cancer	1.74e-05	0.00104	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KIT—bone cancer	1.69e-05	0.00101	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—BRAF—bone cancer	1.59e-05	0.000948	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—EGFR—bone cancer	1.54e-05	0.000919	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PTGS2—bone cancer	1.34e-05	0.000799	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MDM2—bone cancer	1.33e-05	0.000794	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JUN—bone cancer	1.16e-05	0.000691	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MMP9—bone cancer	1.13e-05	0.000672	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—EGFR—bone cancer	9.1e-06	0.000543	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PTGS2—bone cancer	9e-06	0.000537	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—bone cancer	7.64e-06	0.000456	CbGpPWpGaD
